×

Register now for full access to all the content

First Name
Last Name
Company
Title
Country
Thank you for registering!
Error - something went wrong!
   

Nothing Costs More Than Failure: The Benefits of Early Commercial Strategy Development

August 23, 2017

Early commercial strategy during drug development is a critical element of market access planning. If your payer deems the drug ‘benefit not proven’ you could be forced to run more studies or abandon the trial altogether.

The top reasons drugs fail to be recommended for market access are: 

1. Non-robust economics 

2. Uncertain clinical benefit 

3. Inappropriate trial design, comparator, or patient population 

4. Increased drug costs 

5. Safety concerns 

All of these reasons signify the importance of evidenced-based strategy early in the development process and a development partner that keeps market access and reimbursement requirements front of mind. 

Previous Flipbook
3 Steps To A Successful Expanded Access Program
3 Steps To A Successful Expanded Access Program

Find out more about Expanded or Managed Access Programs.

Next Flipbook
An Integrated Pharmacovigilance Model to Meet the New Regulatory Trends
An Integrated Pharmacovigilance Model to Meet the New Regulatory Trends

Learn more about the pharmacovigilance model here!